Abstract: Intracellular deposits of a-synuclein in the form of Lewy bodies are major hallmarks of Parkinson's disease (PD) and a range of related neurodegenerative disorders. Post-translational modifications (PTMs) of a-synuclein are increasingly thought to be major modulators of its structure, function, degradation and toxicity. Among these PTMs, phosphorylation near the C-terminus at S129 has emerged as a dominant pathogenic modification as it is consistently observed to occur within the brain and cerebrospinal fluid (CSF) of post-mortem PD patients, and its level appears to correlate with disease progression. Phosphorylation at the neighboring tyrosine residue Y125 has also been shown to protect against a-synuclein toxicity in a Drosophila model of PD. In the present study we address the potential roles of C-terminal phosphorylation in modulating the interaction of a-synuclein with other protein partners, using a single domain antibody fragment (NbSyn87) that binds to the C-terminal region of a-synuclein with nanomolar affinity. The results reveal that phosphorylation at S129 has negligible effect on Erwin De Genst's current address is AstraZeneca, Innovative Medicines, Discovery Sciences, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK. Tim Guilliams's current address is Healx Ltd., St. John's Innovation Centre, Cowley Road, Cambridge, CB4 0WS, UK. Abbreviations: ITC, isothermal titration calorimetry; NMR, nuclear magnetic resonance; sdAb, nanobody, single-domain antibody; SPR, surface plasmon resonance Additional Supporting Information may be found in the online version of this article. Published by Wiley V C 2018 The Protein Society the binding affinity of NbSyn87 to a-synuclein while phosphorylation at Y125, only four residues away, decreases the binding affinity by a factor of 400. These findings show that, despite the fact that a-synuclein is intrinsically disordered in solution, selective phosphorylation can modulate significantly its interactions with other molecules and suggest how this particular form of modification could play a key role in regulating the normal and aberrant function of a-synuclein.
Introduction
The presence of intracellular aggregated forms of asynuclein in dopaminergic neurons and other brain regions are hallmarks of a series of neurodegenerative disorders, collectively known as synucleinopathies, of which the most common is Parkinson's disease (PD). [1] [2] [3] [4] [5] In PD these intraneuronal proteinaceous inclusion bodies, referred to as Lewy bodies, are composed primarily of fibrillar and aggregated forms of wild-type and post-translationally modified a-synuclein. 1, 2, 6 Various mutations in the gene coding for a-synuclein (including A30P, 7 H50Q, 8, 9 G51D, 10 A53T, 11 and E46K 12 ) are associated with familial forms of the disorder, although they account for only 1-5% of PD cases. 13 Understanding the role of the molecular and structural determinants of the functional and aggregation properties of a-synuclein is therefore pivotal in elucidating the role of this protein in the pathogenesis of PD, as well as identifying novel diagnostic and therapeutic strategies for the treatment of the wider family of synucleinopathies.
It is generally believed that a-synuclein is an intrinsically disordered protein in solution that adopts predominantly a b-sheet conformation when it self-associates into higher order aggregates and amyloid structures. [14] [15] [16] In addition, binding of the protein to lipid bilayers results in its conversion to structures with high a-helical content. [17] [18] [19] Although recent studies have suggested that native asynuclein could exist as a tetramer, subsequent studies have supported previous findings that asynuclein exists predominantly as a disordered monomer. 15, 20 The sequence of a-synuclein can be divided into three distinct regions or domains based on the distribution of charged residues and their functional roles (Fig. 1) . First, a positively charged N-terminal domain (residues 1-60), which contains the sites of many PD associated mutations, comprises imperfect repeats of a conserved sequence motif (KTKEGV). This N-terminal region has a high propensity to form amphipathic a-helical structures upon interaction with lipid membranes and is thought to play a role in regulating the secretion and internalization of a-synuclein. 19, 22, 24 Second, a central amyloidogenic region, termed the nonamyloid b component (NAC), which includes residues 61-95, is highly hydrophobic and is thought to play a key role in aggregation and amyloid formation of a-synuclein. 19, 25 Third, a negatively charged and highly disordered C-terminal region (residues 96-140), has been implicated in regulating a-synuclein nuclear transport 26 and is also thought to play a role in the assembly of SNARE-complexes. 27 Interestingly, most of the binding partners identified for a-synuclein, including proteins, [28] [29] [30] metal ions, 31, 32 and other ligands 33 (such as polyamines), interact with its Cterminal domain. In addition, most known PTMs, including disease-associated modifications, are located in the C-terminal domain, suggesting that this region plays a key role in modulating the functions of a-synuclein in vivo.
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PTMs are increasingly recognized as important modulators of the structural, aggregational, and functional properties of a-synuclein, both in health and disease. [35] [36] [37] Although most of the known asynuclein PTMs have been identified in Lewy bodies, biophysical studies of site-specifically modified proteins have shown that these modifications do not universally enhance a-synuclein aggregation, suggesting that they may be involved in the regulation of normal physiological functions of a-synuclein rather than its aggregation. 38 The majority of published studies have focused primarily on elucidating the effects of phosphorylation on the structure, aggregation, and toxicity of a-synuclein. 35, [39] [40] [41] [42] In this study, we have used strategies that combine recombinant expression, chemical synthesis and native chemical ligation to produce a-synuclein that is site specifically phosphorylated at Y125 and S129, in order to investigate how these commonly detected and well-studied C-terminal modifications influence the interaction of a-synuclein with a specific protein binding partner.
As an example of an a-synuclein protein-protein interaction, we used the recently generated camelid antibody fragment (nanobody), NbSyn87. 21 NbSyn87 binds with nanomolar affinity to the C-terminal domain of a-synuclein, near the phosphorylation sites Y125 and S129, 21 enabling us to investigate
El Turk et al.
the impact of these two modifications on a specific protein-protein interaction. We have studied the effects of a-synuclein phosphorylation on binding to NbSyn87 by using isothermal calorimetry (ITC), surface plasmon resonance (SPR), and nuclear magnetic resonance (NMR) spectroscopy. Furthermore, we have sought to determine whether or not the phosphorylation-mimicking mutation, S129E, and the phosphorylation-blocking mutation, S129A, commonly used to probe the effects of phosphorylation of a-synuclein in vivo, reproduce the effects of asynuclein phosphorylation on its interactions with NbSyn87. Our results demonstrate, that despite the proximity of these two C-terminal modification sites, the binding of NbSyn87 is affected very differently by the addition of phosphate groups to Y125 or S129. As well as demonstrating the highly selective effects on binding of the position of phosphorylation, our findings suggest that NbSyn87 could be a useful probe to evaluate the effects of a-synuclein PTMs on its structure and toxicity.
Results
We have shown previously that polo-like kinases 2 and 3 (PLK2 and PLK3) can phosphorylate asynuclein selectively at S129 with great efficiency (>95%). 43 In contrast, little is known about kinases that can potently phosphorylate a-synuclein at Y125 in a selective manner. Therefore, a-synuclein phosphorylated at Y125 was prepared using semisynthetic strategies, as described previously. 36 15 N labeled pY125 a-synuclein for NMR experiments was prepared in vitro by site-specifically phosphorylating the Y133F/Y136F a-synuclein double mutant, using the Syk kinase, which is known to phosphorylate at three C-terminal tyrosine residues. 36 Binding of NbSyn87 to a-synuclein by ITC We used ITC to measure the thermodynamic parameters of the binding of NbSyn87 nanobody to the wild type, pY125, S129A, S129E, and pS129 forms of a-synuclein. The data shown in Figure 2 (Table I) , is very similar to that of the wild type protein, and only small differences in binding enthalpy and entropy were observed.
Binding of NbSyn87 to a-synuclein by SPR
In order to extend the conclusions from the ITC data and to explore the kinetics of the interaction between NbSyn87 and the a-synuclein variants, we carried out SPR experiments (Fig. 3 , Table II ). These experiments confirm that phosphorylation or mutations at S129 have little or no effect on interactions with NbSyn87 while phosphorylation of Y125 results in a dramatic reduction in affinity. The SPR traces obtained for the wild type protein and the S129A, S129E, and pS129 variants ( 44 Only small differences were observed between the binding of the S129 variants and wild type a-synuclein to NbSyn87, supporting the conclusion that S129 is not an important determinant of the interaction. Interestingly, all modifications at this position led to a reduction in both k on and k off , to a maximum of about 2.5-fold for pS129. In contrast, for pY125, very weak binding to NbSyn87 precluded the accurate measurement of rate constants, although, a thermodynamic analysis of the equilibrium resonance unit values yielded a K d of greater than 1 mM, that is at least a 66-fold reduction in affinity (Fig. 3 , Table II ), confirming that phosphorylation at this site significantly weakens interactions with the nanobody.
NMR studies of the binding interaction
We have previously mapped the epitope for NbSyn87 on wild type a-synuclein by considering the effects of the backbone amide resonances as an indication of binding. 21 We observed in this study both broadening and chemical shift perturbations of the resonances of residues located at the C-terminal region of asynuclein, including residues 118-140. 21 To determine the effects of S129 and Y125 phosphorylation on the mode of interaction of NbSyn87 and a-synuclein, 1 H 15 N HSQC spectra of the wild type, the Y133F/ Y136F variant and the phosphorylated Y125 and S129 forms of a-synuclein were measured in the presence and absence of saturating concentrations of NbSyn87. Figure S1 (Supporting Information) shows that the 1 H 15 N HSQC spectra of the Y133F/Y136F, pY125, and pS129 variants are virtually identical to that of wild type a-synuclein, with all the resonances of the amide protons values falling between 7.8 and 8.8 ppm, a typical feature of unstructured proteins. As reported previously, a-synuclein in aqueous solution behaves as an intrinsically disordered protein with and without phosphorylation at Y125 and S129 (Fig. S1 , Supporting Information). Nevertheless, slight perturbations in chemical shifts are observed for residues in the vicinity of the phosphorylation site, which are likely to result from the change in the covalent structure of the protein upon the introduction of the phosphate group (Fig. 4, S1 , Supporting Information). It is noteworthy, however, that the resonances affected, in both phosphorylated a-synuclein variants, are located within the epitope region of a-synuclein for NbSyn87. for the binding of NbSyn87 to pY125 a-synuclein for concentrations ranging from 2500 to 0 nM (᭜), for the binding of NbSyn87 to S129A a-synuclein (w) for concentrations ranging from 625 to 0 nM, and for the binding of NbSyn87 to wild type a-synuclein (᭡), for concentrations ranging from 2500 to 0 nM.
It has been reported previously that saturation of the binding of a-synuclein is achieved with a molar equivalent of NbSyn87. 21 Therefore, to validate our ITC and SPR results and to confirm the effects of Y125 and S129 phosphorylation on the binding of NbSyn87 to a-synuclein, we recorded 1 H 15 N HSQC spectra of the different 15 N-labeled asynuclein variants containing equimolar concentrations of NbSyn87. As with the wild type protein, both pS129 and Y133F/Y136F forms of a-synuclein were saturated with an equimolar concentration of NbSyn87, and displayed fundamentally identical spectra to that of the wild type protein bound to NbSyn87 (Fig. 5) . In particular, the residues within the epitope (residues 118-140) displayed similar broadening even at equimolar concentration of NbSyn87. Interestingly, to achieve effective saturation of the pY125 a-synuclein variant with NbSyn87, 1.4M equivalents of NbSyn87 were required, suggesting that pY125 a-synuclein and NbSyn87 bind with lower affinity, consistent with the data obtained by ITC and SPR. The spectrum of the pY125 a-synuclein variant when saturated with NbSyn87 showed identical broadening of residues 118-140 to that of the wild type protein saturated with the nanobody (Fig. 5) . The fraction of protein bound to NbSyn87 was calculated using the saturation molar ratio obtained by NMR (1.4) and the value of the dissociation constant (K d ) obtained by ITC (6 mM) and SPR (1 mM); the values obtained were 0.90 and 0.99, respectively. Thus, the higher concentration of the nanobody required for saturation is also consistent with the lower binding affinity observed in both the ITC and SPR experiments.
Discussion
The combination of advances in the fields of peptide synthesis and chemical ligation has made it possible to produce proteins with site-specific PTMs, enabling the study of the effects of such modifications on the structure and binding properties of proteins. 35, 36 In the present study, these recent developments have enabled site-specific phosphorylation of a-synuclein and hence have allowed the investigation of the effects of these modifications on its interactions with other proteins. Several kinases that phosphorylate the C-terminal serine and residues Y125, Y133, and Y136, in vitro, have been identified, although only phosphorylation events at Y125 and pS129 have 40 It has also been shown that phosphorylation at Y125 in transgenic Drosophila expression of wild type human a-synuclein protects against neurotoxicity. 40 Additionally, age-related decreases in the levels of the pY125 variant have been identified in both human subjects and transgenic fly models of PD, and indeed this phosphorylated state has not been found in the brains of patients with Lewy body dementia. 40 In contrast, phosphorylation at S129 has been consistently reported as the most commonly detected and abundant modification of a-synuclein in Lewy bodies. In addition, the level of S129 phosphorylation correlates with pathology in animal models of PD and disease progression in human studies.
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Phosphorylation of Y125 or S129 results in different effects on the modulation of a-synuclein interactions with NbSyn87. Previous studies of the binding interactions of a-synuclein have mostly relied on coimmunoprecipitation and yeast two-hybrid screening techniques. [46] [47] [48] These methodologies may, however, be insufficient to identify the physiological and pathological interactions of a-synuclein or to probe the structural state of the protein that is involved in binding. [46] [47] [48] The use of a nanobody raised to bind to the Cterminal domain of a-synuclein 21 has enabled us to quantify the effects of phosphorylation at S129 and Y125 on a model a-synuclein interaction in detail. The results obtained using ITC, SPR, and NMR spectroscopy have revealed that phosphorylation of Y125 affects very significantly the affinity of NbSyn87 for asynuclein. In contrast, phosphorylation of S129, located just four residues away in the a-synuclein sequence and very close to the epitope for NbSyn87, has no significant effects on the binding affinity. The ITC results obtained for the interaction of pY125 compared to the wild type protein show a dramatic change in the binding enthalpy (Table I ). In contrast, no detectable changes to the binding enthalpy or entropy were observed for the S129 a-synuclein variants (Table  I ). These findings demonstrate that the impact of phosphorylation on the interaction of a-synuclein with a given protein partner can be extremely site-specific, despite its largely unstructured nature. This suggests that C-terminal modifications of a-synuclein could be a mechanism for fine-tuning its interactions with binding partners and regulating its biological activity.
Because the binding of a-synuclein to NbSyn87 leads to extensive broadening of the NMR cross peaks of the residues between V118 and P140 in the 1 H- 15 N HSQC spectrum of the protein, it has not been possible to elucidate in detail the structural effects of NbSyn87 on the phosphorylated variants within the binding region (Fig. S1 , Supporting Information). Nonetheless, the NMR experiments provide further confirmation of phosphorylation-dependent changes in nanobody affinity, via an examination of the concentration of NbSyn87 needed to saturate the panel of a-synuclein variants. Our findings reveal no significant differences in the molar ratios needed to reach effective saturation of NbSyn87 binding to the wild type protein and the S129 a-synuclein variants (S129A and S129E, and the phosphorylated species pS129), confirming the conclusion that phosphorylation or mutation of S129 does not detectably influence the interactions of a-synuclein with the nanobody. Titration of the pY125 variant of asynuclein with NbSyn87, reached saturation only at a 2:3 a-synuclein:nanobody ratio consistent with a significant drop in affinity.
Although no changes in the binding enthalpy or in the binding entropy are observed for the pS129 variant, the loss of the binding affinity of NbSyn87 for pY125 a-synuclein can be attributed to the fact that addition of the phosphate group to Y125 increases the negative charge on the protein as well as the steric bulk of the tyrosine side chain. The Y133F/Y136F mutant exhibited similar binding affinity as the wild type protein, as confirmed by the ITC data (Fig. S2, Supporting Information) , confirming that the effect seen by NMR spectroscopy on the pY125 a-synuclein variant is a specific consequence of the phosphorylation of this residue.
The C-terminal region of a-synuclein is a hub for many binding proteins, small molecules, and metal ions 32, 34, [49] [50] [51] and governs intra-molecular long-range contacts within a-synuclein [52] [53] [54] itself. It has furthermore been found to regulate interactions with other proteins involved in SNARE complex assembly and neurotransmitter release. 27, 34, 55 Thus, by harboring two phosphorylation sites that can be discriminated by a protein partner, our findings demonstrate the potential role of PTMs in the Cterminal domain as molecular switches for regulating a-synuclein interactions and functions.
Implications for PD diagnostics and therapeutic strategies
Due to its ability to differentiate between the pS129 and pY125 forms of a-synuclein, NbSyn87 has the potential to be developed as a method for discriminating pathological from physiologically-benign states of a-synuclein. This finding lays the groundwork for potentially important immunological and vaccine development strategies, approaches that have recently received considerable attention because of their reported potential to ameliorate neurodegenerative diseases. [56] [57] [58] Recently, antibodies targeting asynuclein have been shown to be sensitive indicators of neurodegeneration, suggesting that they may have a role in protecting against disease and hence have the potential for therapeutic applications. 59 In addition, discrimination between two sites of phosphorylation on nearby residues by antibodies has been shown to be invaluable in diagnostic and therapeutic research, for example the cardiac muscle protein phospholamban 60 and the tau protein in Alzheimer's disease. 61 The single domain antibody used in this study represents a novel and promising alternative to conventional antibodies for PD diagnostic and therapeutic applications. Its small molecular size (ca. 14 kDa), reflects the fact that it is composed of a single domain antigen recognition motif. Nevertheless, NbSyn87 has a binding affinity that is comparable to that of conventional antibodies. 62, 63 Moreover, nanobodies are generally extremely stable and have low immunogenicity because of their high sequence similarity with the human VH family III domains. 64 A number of earlier studies have reported the ability of nanobodies to modulate the conformation of proteins both in vitro and in living cells, and have established their potential as therapeutic agents, for example in rheumatoid arthritis, chronic colitis, and Alzheimer's disease. 56, [65] [66] [67] [68] [69] Our findings provide new insights into the potential applications of NbSyn87 in diagnostic and therapeutic strategies based on two variants of a-synuclein that are associated with opposite effects on the pathogenicity of a-synuclein.
In conclusion, studies using ITC, SPR, and NMR spectroscopy have provided direct evidence that phosphorylation can significantly influence the interaction of a-synuclein with its binding partners. Moreover, the results suggest that the impact of phosphorylation on the interaction of a-synuclein with a specific protein partner can be very significant and highly site specific and underscore the critical importance of conducting systematic studies to investigate the role of PTMs in modulating the asynuclein proteome in health and disease.
Materials and Methods

Materials
All reagents were purchased from Sigma-Aldrich (Dorset, England), unless otherwise stated. Protein concentrations were measured by UV absorbance spectroscopy using molecular extinction coefficients calculated using the ExPASy-ProtParam method (http://web.expasy.org/protparam/). The extinction coefficients at 280 nm of the wild type, pS129, S129E, and S129A a-synuclein variants were all taken to be 5960 M 21 cm
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. Generation of wild type a-synuclein a-Synuclein in its unlabeled and 15 N labeled forms was prepared according to previously published procedures.
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Generation of semisynthetic pY125 a-synuclein Semisynthetic pY125 a-synuclein was generated according to a previously published procedure. Generation of 1 H 15 N labeled S129E and S129A a-synuclein 15 N labeled S129E and S129A a-synuclein variants were purified according to previously published procedures. 36 Isolation, expression, and purification of the antibody fragment NbSyn87
The expression and purification of NbSyn87 was performed as described previously. 21 Briefly, NbSyn87, obtained from dromedary immunization and isolated through phage display selection, 71, 72 was expressed in the periplasm of E. coli and purified using immobilized metal affinity and sizeexclusion chromatography according to published protocols. 21, 72 ITC measurements of binding affinity Calorimetric data were recorded using an iTC200 calorimeter (MicroCal, LLC, Northampton, MA). A solution of 40 lL of NbSyn87 at a concentration of 150 lM was titrated in 2 lL aliquots at 150 s intervals into a calorimetric cell containing a standard volume (203 lL) of 10 lM a-synuclein in solution.
Experiments were performed at 258C in 10 mM phosphate and 150 mM sodium chloride at a pH of 7.4. The thermodynamic analysis was performed using the MicroCal analysis software (Origin 7.0) using a simple 1:1 bimolecular binding model.
Kinetic and affinity measurements using SPR
The kinetic constants of the interaction of NbSyn87 with wild type, pY125, S129A, S129E, and pS129 asynuclein variants were determined by SPR (Biacore 3,000, GE Healthcare, Sweden). On one CM5 chip, wild type a-synuclein, and the S129A and S129E variants, were immobilized in flow-cells 2, 3, and 4, respectively, at 50 resonance units (50 pg/mm 2 ) via EDC/NHS chemistry and according to the manufacturer's recommendations. Flow-cell 1 of the chip contained no protein and served as a blank reference cell. Similarly, a second CM5 chip was prepared with wild type a-synuclein, pS129 and S129E immobilized in respectively flow-cell 2, 3, and 4. For both chips, triplicate association traces of NbSyn87 for concentrations ranging from 0 to 227 mM were recorded for 2 min in a buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% Tween 20 and 3 mM EDTA; triplicate dissociation traces of the complexes in the buffer were recorded for 5 min. The curves obtained after subtraction of the signals of the reference cell (the flow cell that contained no immobilized protein) and injection of buffer, were then fitted to a 1:1 Langmuir binding model with the program BIAeval (Biacore). In addition, the equilibrium values of the association binding traces were plotted versus the concentration of NbSyn87 for each variant, and fitted to a 1:1 bimolecular binding isotherm, to obtain the affinity constant for the NbSyn87:a-synuclein interactions, independently of the binding kinetics. For the measurement of the pY125 a-synuclein:NbSyn87 interaction, a separate chip was prepared with 100 RU of immobilized wild type a-synuclein (flow-cell 2) and S129A (flowcell 3), and 50 RU of pY125 a-synuclein (flow-cell 4). Binding traces of NbSyn87 concentrations ranging from 2500-0 nM were subsequently recorded and evaluated as described above. 
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